MEDP Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

689.39M

+28.48%

4.182

+13.96%

679.00M

+21.56%

3.818

+4.04%

690.52M

+14.46%

4.094

+32.06%

Estimates Revision

The market is revising Upward the revenue expectations for Medpace Holdings, Inc. (MEDP) for FY2025, with the revenue forecasts being adjusted by 1.95% over the past three months. During the same period, the stock price has changed by 12.63%.

Revenue Estimates for FY2025

Revise Upward

+1.95%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+5.27%

In Past 3 Month

Stock Price

Go Up

+12.63%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast MEDP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MEDP is 524.89 USD with a low forecast of 425.00 USD and a high forecast of 655.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

7 Hold

2 Sell

Hold

Current: 559.110

Low

425.00

Averages

524.89

High

655.00

Current: 559.110

Low

425.00

Averages

524.89

High

655.00

Barclays

Luke Sergott

Underweight

maintain

$485 -> $525

2025-12-15

New

Reason

Barclays

Luke Sergott

Price Target

$485 -> $525

2025-12-15

New

maintain

Underweight

Reason

Barclays analyst Luke Sergott raised the firm's price target on Medpace to $525 from $485 and keeps an Underweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

BMO Capital

Market Perform

initiated

$600

2025-11-12

Reason

BMO Capital

Price Target

$600

2025-11-12

initiated

Market Perform

Reason

BMO Capital initiated coverage of Medpace with a Market Perform rating and $600 price target. The firm views the stock's valuation as full in a "tepid" biotech funding backdrop. The shares at current levels leave "little cushion for additional potential macro volatility," the analyst tells investors in a research note.

Truist

Jailendra Singh

Hold

maintain

$436 -> $555

2025-10-27

Reason

Truist

Jailendra Singh

Price Target

$436 -> $555

2025-10-27

maintain

Hold

Reason

Truist analyst Jailendra Singh raised the firm's price target on Medpace to $555 from $436 and keeps a Hold rating on the shares after meeting with its management team to discuss Q3 results, book-to-bill targets, and expectations for 2026. The firm's higher assumed forward earnings multiple at 20-tims vs. 18-times prior reflects its increased confidence in the continuing recovery in the Biotech market, the analyst tells investors in a research note.

Baird

Neutral

maintain

$491 -> $613

2025-10-24

Reason

Baird

Price Target

$491 -> $613

2025-10-24

maintain

Neutral

Reason

Baird raised the firm's price target on Medpace to $613 from $491 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results.

TD Cowen

Sell

maintain

$356 -> $462

2025-10-24

Reason

TD Cowen

Price Target

$356 -> $462

2025-10-24

maintain

Sell

Reason

TD Cowen raised the firm's price target on Medpace to $462 from $356 and keeps a Sell rating on the shares. The firm saidthe company's preliminary 2026 outlook as well as cancels being "well-behaved" and pre-backlog pipeline value growth of 30% year-over-year is a positive sign for the company's fundamental outlook.

Barclays

Luke Sergott

Underweight

maintain

$425 -> $485

2025-10-24

Reason

Barclays

Luke Sergott

Price Target

$425 -> $485

2025-10-24

maintain

Underweight

Reason

Barclays analyst Luke Sergott raised the firm's price target on Medpace to $485 from $425 and keeps an Underweight rating on the shares following the earnings report. The firm says it was "overly bearish" on Medpace's demand environment.

Valuation Metrics

The current forward P/E ratio for Medpace Holdings Inc (MEDP.O) is 33.94, compared to its 5-year average forward P/E of 30.13. For a more detailed relative valuation and DCF analysis to assess Medpace Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

30.13

Current PE

33.94

Overvalued PE

35.63

Undervalued PE

24.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

22.47

Current EV/EBITDA

26.28

Overvalued EV/EBITDA

26.32

Undervalued EV/EBITDA

18.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.50

Current PS

5.67

Overvalued PS

5.33

Undervalued PS

3.66

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress areSelling! The selling amount has increased100%over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MEDP News & Events

Events Timeline

No data

News

3.0

12-11NASDAQ.COM

Reasons to Retain Fresenius Medical Stock in Your Portfolio for the Time Being

9.0

12-11NASDAQ.COM

BEAT Receives FDA Approval for First Wireless At-Home 12-Lead ECG Device

3.0

12-09NASDAQ.COM

Reasons to Keep OPKO Health Stock in Your Portfolio at This Time

People Also Watch

Frequently Asked Questions

What is Medpace Holdings Inc (MEDP) stock price today?

The current price of MEDP is 559.11 USD — it has increased 0.22 % in the last trading day.

What is Medpace Holdings Inc (MEDP)'s business?

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.

What is the price predicton of MEDP Stock?

What is Medpace Holdings Inc (MEDP)'s revenue for the last quarter?

Medpace Holdings Inc revenue for the last quarter amounts to 659.90M USD, increased 23.74 % YoY.

What is Medpace Holdings Inc (MEDP)'s earnings per share (EPS) for the last quarter?

Medpace Holdings Inc. EPS for the last quarter amounts to 3.86 USD, increased 28.24 % YoY.

What changes have occurred in the market's expectations for Medpace Holdings Inc (MEDP)'s fundamentals?

How many employees does Medpace Holdings Inc (MEDP). have?

Medpace Holdings Inc (MEDP) has 5900 emplpoyees as of December 15 2025.

What is Medpace Holdings Inc (MEDP) market cap?

Today MEDP has the market capitalization of 15.72B USD.